Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Multicenter Study of Durvalumab + Tremelimumab With Chemoradiation in Advanced Solid Tumors
jRCT2080223930Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1 trial of durvalumab and tremelimumab in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 1 more, sponsored by AstraZeneca. Started Jun 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)advanced nonhematological malignancy
Beyond the preview
Go deeper on jRCT2080223930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223930.